Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

AMD-3100 improves the eligibility of MM patients for stem cell transplantation

June 23, 2004

FDA accepts Genmab IND for phase I/II study of HuMax-CD20 in CLL

June 22, 2004

Phase II data supports progression of Onyvax-P for advanced prostate cancer

June 22, 2004

Full enrollment in phase III Virulizin trial

June 21, 2004

PSMA-targeting immunotherapies presented at ASCO

June 21, 2004

Insegia chosen as trade name for G17DT

June 18, 2004

Polyvalent vaccine reported to improve survival in advanced melanoma

June 18, 2004

Pivotal phase III trial of Rencarex for renal cell carcinoma opens enrollment

June 17, 2004

Synergistic effects of IL-21 and rituximab in B-lymphoma cell lines

June 17, 2004

An EGF vaccine reported to improve survival in advanced lung cancer

June 17, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...